fluoxymesterone Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Fluoxymesterone, sold under the brand names Halotestin and Ultandren among others, is a synthetic, orally active androgenic-anabolic steroid (AAS) and a 17α-alkylated derivative of testosterone developed by Pharmacia & Upjohn Company LLC, approved by FDA at 1956. Fluoxymesterone is used in the treatment of hypogonadism in males and breast cancer in women. Fluoxymesterone has a relatively high ratio of androgenic to anabolic activity similarly to testosterone. Like many 17α-alkylated AAS, it has a relatively low affinity for the androgen receptor (AR). However, its actions are mediated by the AR, most likely due to its relatively long elimination half-life of approximately 9.2 hours.   NCATS

Chemistry

  • SMILES: C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
  • InChIKey: YLRFCQOZQXIBAB-RBZZARIASA-N
  • Mol. Mass: 336.4409
  • ALogP: 3.33
  • ChEMBL Molecule:
    fluoxymesterone  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

11beta,17beta-dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one | 17alpha-methyl-9alpha-fluoro-11beta-hydroxytesterone | 17α-methyl-9α-fluoro-11β-hydroxytesterone | 9alpha-fluoro-11beta-hydroxy-17-methyltestosterone | 9-fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one | androfluorene | androfluorone | android-f | androxy | fluotestin | fluoximesterona | fluoximesterone | fluoxymesterone | fluoxymesteronum | halotestin | ora-testryl | testosterone, 9-fluoro-11beta-hydroxy-17-methyl-

Organizations (8)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (5)


 

Breast Neoplasms (approved 1956)

Hypogonadism (approved 1956)

Neoplasms

Orchitis

Puberty, Delayed (approved 1956)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue